Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/008044
Kind Code:
A1
Abstract:
A compound, which is a compound represented by formula (I) or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound represented by formula (I) can significantly inhibit Mpro or inhibit coronavirus replication, and has good metabolic stability.

More Like This:
Inventors:
YU YANG (CN)
XUE DING (CN)
LIU WEI (CN)
Application Number:
PCT/CN2023/105562
Publication Date:
January 11, 2024
Filing Date:
July 03, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
TENCENT TECH SHENZHEN CO LTD (CN)
International Classes:
C07K5/027; A61K31/407; A61P31/14; C07D491/20; C07K5/097
Domestic Patent References:
WO2007001406A22007-01-04
WO2022013684A12022-01-20
Foreign References:
US20220380377A12022-12-01
CN114805478A2022-07-29
CN114426568A2022-05-03
US20220062232A12022-03-03
Other References:
OWEN DAFYDD R., ALLERTON CHARLOTTE M. N., ANDERSON ANNALIESA S., ASCHENBRENNER LISA, AVERY MELISSA, BERRITT SIMON, BORAS BRITTON, : "An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 374, no. 6575, 24 December 2021 (2021-12-24), US , pages 1586 - 1593, XP093025782, ISSN: 0036-8075, DOI: 10.1126/science.abl4784
Attorney, Agent or Firm:
BEIJING LISENG INTELLECTUAL PROPERTY AGENCY LTD. (CN)
Download PDF: